Updating the progress of Argos’ dendritic cell immunotherapies in development to treat cancer, infectious and autoimmune diseases


Guest: Jeffrey Abbey, President & CEO, Argos Therapeutics, Inc., Durham, NC

abbey2010photo.jpg
Jeffrey Abbey, President & CEO, Argos Therapeutics, Inc., Durham

Argos Therapeutics, Inc.

Advertisements